Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Sees Large Drop in Short Interest

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totaling 123 shares, a drop of 64.6% from the April 30th total of 347 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 21 shares, the days-to-cover ratio is presently 5.9 days.

Orion OYJ Stock Performance

Shares of ORINY remained flat at $37.99 during mid-day trading on Friday. 19 shares of the stock were exchanged, compared to its average volume of 17. Orion OYJ has a 1 year low of $25.95 and a 1 year high of $42.75. The firm has a market capitalization of $10.72 billion, a PE ratio of 17.43 and a beta of 0.09. The stock’s 50 day moving average price is $38.23 and its two-hundred day moving average price is $37.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 1.77.

Orion OYJ (OTCMKTS:ORINY) last released its earnings results on Thursday, April 23rd. The company reported $0.37 EPS for the quarter. The company had revenue of $488.80 million for the quarter. Orion OYJ had a net margin of 27.14% and a return on equity of 49.17%.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.